lunedì, 4 maggio 2026

Notizie AIOM – anno XV

Scuola civica di alta formazione. Diritti e partecipazione in sanità

Parte a settembre, con quattro percorsi brevi dedicati a temi e questioni centrali per la sanità, la ‘Scuola civica di alta formazione. Diritti e partecipazione in sanità’, iniziativa del Tribunale dei diritti del malato di Cittadinanzattiva per ...
Leggi tutto

Premio ai 4 migliori progetti di ricerca in artrite psoriasica, psoriasi, mieloma multiplo e carcinoma del pancreas

Il concorso è destinato a medici o biologi di età inferiore o uguale a 40 anni Realizzato in collaborazione con le Società Scientifiche AIOM, SIDeMaST, SIE e SIR Scadenza presentazione progetti: 15 settembre 2017

ASCO Updates Treatment Guidelines for Advanced NSCLC

August 15, 2017 - ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer (NSCLC). The organization has created new recommendations regarding the use of immunotherapy, and updated advice on targeted ...
Leggi tutto

ASCO Guideline on Stage IV NSCLC Therapy Updated

August 16, 2017 - An update of the ASCO clinical practice guideline on the systemic treatment of patients with stage IV non–small cell lung cancer (NSCLC) clarifies the role of immunotherapy in this setting. The update, published by Hanna et al in the Journal of Clinical ...
Leggi tutto

FDA Grants Venetoclax Breakthrough Designation for AML Subpopulation

July 28, 2017 - Venetoclax has received an FDA breakthrough therapy designation for use in combination with low dose cytarabine (LDAC) in treatment-naïve elderly patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy, according to Roche, ...
Leggi tutto

FDA Grants Durvalumab Breakthrough Designation for NSCLC

July 31, 2017 - The FDA has granted durvalumab a breakthrough therapy designation to treat patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation. AstraZeneca and its global ...
Leggi tutto

FDA Awards Acalabrutinib Priority Review in MCL

August 2, 2017 - The FDA has granted a priority review to a new drug application (NDA) for acalabrutinib for patients with previously-treated mantle cell lymphoma (MCL), according to AstraZeneca, the manufacturer of the highly selective, potent BTK inhibitor. The announcement ...
Leggi tutto

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16, 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for brentuximab vedotin for the treatment of patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate ...
Leggi tutto

FDA Approves Olaparib Tablets for Ovarian Cancer

August 17, 2017 - The FDA has approved olaparib tablets as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy, regardless of BRCA status. ...
Leggi tutto

European Commission Approves Frontline Fulvestrant for ER+ Breast Cancer

July 27, 2017 - The European Commission (EC) has approved the use of fulvestrant to treat estrogen receptor (ER)-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. The EC based its decision on results ...
Leggi tutto